Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

  
 
  
Reply to this topic

PAR, Paradigm Pharmaceuticals
nipper
post Posted: Jan 11 2021, 12:58 PM
  Quote Post


Posts: 7,962
Thanks: 2652


some in depth look under the bonnet for PAR
https://www.fiftyonecapital.com/paradigm-20...maceuticals-ltd
QUOTE
.....a structural study on PPS by Degenhardt M et al shows the differences between one competitors product & bene's PPS. The study showed the difficulties that other manufacturers have in replicating PPS, by confirming that the competitors' batches did not match the PPS monograph of benes.

Degenhardt also noted that "minor variations in the molecular shape and size of a drug can have profound effects on its pharmacological activities." Therefore the FDA and other regulators have yet to approve other generic PPS manufactures.

.
QUOTE
CONCLUSION


To simplify our view, we see it like this:
Paradigm has exclusive access to a drug (PPS) that has an excellent safety profile and multiple methods of action (i.e. could be used in multiple different indications) that have presently been under-explored. Focused on re-purposing PPS, Paradigm have developed a strong partnership with the only FDA approved supplier of PPS. This partnership (moat) adds another layer of protection to the company over and above their patent portfolio, creating a unique monopolistic situation should the company successfully commercialise products using PPS.

As research begins in potential new indications using PPS, Paradigm seems the obvious choice to commercialise any that show promise, effectively cornering the market for this multi-method of action molecule. After learning more about PPS and after discussions with KOLs and researches, we realise that we drastically underestimated how many indications PPS could potentially work within. While it is still early days, the successful OA trial is the first step towards a long and robust pipeline of potentially new indications that Paradigm could commercialise products for using PPS.

We really do believe the best years are ahead for Paradigm and that the recent clinical trial success is the first step in what should be a long and fruitful journey. Once products are commercialised the repeat use (recurring revenue) and huge markets should see revenue and profit grow exponentially. It's not often you find a company that has tremendous potential to grow into a multi-billion dollar pharmaceutical enterprise, and for those investors who have the foresight and patience to enjoy the journey, we believe will be thoroughly rewarded.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
plastic
post Posted: Jan 22 2020, 04:11 AM
  Quote Post


Posts: 10,543
Thanks: 306


Is this the QRx reincarnation?



--------------------
What did Uncle Mel do to us?
 
nipper
post Posted: Sep 27 2019, 10:02 AM
  Quote Post


Posts: 7,962
Thanks: 2652


QUOTE
Paradigm Biopharmaceuticals (PAR) $2.52

Another [pain relief aspirant] is the $394million market worth of Paradigm, which is seeking to repurpose an old deep-vein thrombosis drug for osteoarthritis pain. So far the compound, renamed Zilosul has worked wonders with the creaking knees and joints of ex-footballers including former Carlton great Greg Williams, while fellow Brownlow Medallist Chris Judd and ‘Leaping’ Leo Barry have invested in the company.

The drug is not approved and only available under a special access theme and is subject to two separate trials. “Real-world evidence” of 205 patients with knee osteoarthritis suggests pain reduction of more than 50 percent.

This month the company won US Food & Drug Administration assent to treat ten more patients under compassionate use status. The treating physician, Dr. John Michel is a former player with the National Football League club, the Green Bay Packers.

Given Paradigm shares have tripled in the last year and risen more than six-fold since listing four years ago, punters are warming to Paradigm’s anti-opioid shtick. If approved, and it’s a big if, Zilosul would be worth billions.
Tim Boreham



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING